Figure 8
Low-dose enzastaurin markedly decreases tumor growth and angiogenesis in a xenograft mouse model. Beige-nude Xid mice were given subcutaneous inoculations in the right flank with 3 × 107 MM.1S cells. Treatment by oral gavage (vehicle alone or 30 mg/kg enzastaurin twice daily) was started when tumors were measurable. (A) Tumor burden was measured every alternate day using a caliper. Tumor volume is presented as means ± SE. (B) Survival was evaluated using Kaplan-Meier curves and log-rank analysis. (C) Body weight was evaluated 3 times a week. (D-F) Representative microscopic images of tumor sections are shown stained with hematoxylin and eosin (D), CD31 (E), and TUNEL (F).

Low-dose enzastaurin markedly decreases tumor growth and angiogenesis in a xenograft mouse model. Beige-nude Xid mice were given subcutaneous inoculations in the right flank with 3 × 107 MM.1S cells. Treatment by oral gavage (vehicle alone or 30 mg/kg enzastaurin twice daily) was started when tumors were measurable. (A) Tumor burden was measured every alternate day using a caliper. Tumor volume is presented as means ± SE. (B) Survival was evaluated using Kaplan-Meier curves and log-rank analysis. (C) Body weight was evaluated 3 times a week. (D-F) Representative microscopic images of tumor sections are shown stained with hematoxylin and eosin (D), CD31 (E), and TUNEL (F).

Close Modal

or Create an Account

Close Modal
Close Modal